These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28070733)

  • 61. Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy.
    Wu R; Wu Z; Xing L; Liu X; Wu L; Zhou Z; Li L; Huang Y
    Asian J Pharm Sci; 2022 Aug; 17(5):653-665. PubMed ID: 36382301
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.
    Kiiskinen U; Matthaei S; Reaney M; Mathieu C; Ostenson CG; Krarup T; Theodorakis M; Kiljański J; Salaun-Martin C; Sapin H; Guerci B
    Clinicoecon Outcomes Res; 2013; 5():355-67. PubMed ID: 23874113
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.
    Brice R; Shelley S; Chaturvedi P; Glah D; Ashley D; Hadi M
    Drugs Context; 2015; 4():212269. PubMed ID: 25657811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.
    Kalra S; Das AK; Sahay RK; Baruah MP; Tiwaskar M; Das S; Chatterjee S; Saboo B; Bantwal G; Bhattacharya S; Priya G; Chawla M; Brar K; Raza SA; Aamir AH; Shrestha D; Somasundaram N; Katulanda P; Afsana F; Selim S; Naseri MW; Latheef A; Sumanatilleke M
    Diabetes Ther; 2019 Oct; 10(5):1645-1717. PubMed ID: 31359367
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.
    Ishii H; Niiya T; Ono Y; Inaba N; Jinnouchi H; Watada H
    Diabetol Metab Syndr; 2017; 9():3. PubMed ID: 28074109
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 69. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study.
    Cegla J
    Ann Clin Biochem; 2016 Jul; 53(4):518. PubMed ID: 28071092
    [No Abstract]   [Full Text] [Related]  

  • 71. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Hunt B; Vega-Hernandez G; Valentine WJ; Kragh N
    Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
    Evans M; Chubb B; Gundgaard J
    Diabetes Ther; 2017 Apr; 8(2):275-291. PubMed ID: 28210866
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
    Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
    Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
    Suzuki S; Oura T; Takeuchi M; Boye KS
    Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.
    Raccah D
    Diabetes Metab; 2017 Apr; 43(2):110-124. PubMed ID: 28169086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.